| Literature DB >> 31362471 |
In Tae So1, Yoo Jin Lee1, Hye In Jung1, Jae Seok Hwang1, Byoung Kuk Jang1.
Abstract
BACKGROUND/AIMS: Many patients uses the internet to obtain information about their diseases. However, there is increasing concern regarding the quality of internet information. Thus, we aimed to systematically evaluate the quality of websites containing educational information about non-alcoholic fatty liver disease (NAFLD) in Korea.Entities:
Keywords: Information resource guide; Internet; Non-alcoholic fatty liver disease
Mesh:
Year: 2019 PMID: 31362471 PMCID: PMC7820651 DOI: 10.3904/kjim.2018.359
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Description of the components of the quality evaluation instrument (QEI) used to evaluate websites with information on NAFLD (scores range from 0 to 56)
| Defines NAFLD | ||||||||
| Describes NAFLD as term that includes non-alcoholic fatty liver, NASH and non-alcoholic fatty liver associated cirrhosis (1) | ||||||||
| Define significant alcohol intake amount differentiate from alcoholic liver disease (2) | ||||||||
| Epidemiology of NAFLD | ||||||||
| Discusses incidence and prevalence of NAFLD | ||||||||
| Incidence (3) | ||||||||
| Prevalence (4) | ||||||||
| Discusses risk factor of NAFLD | ||||||||
| Obesity (5) | ||||||||
| Diabetes mellitus type II (6) | ||||||||
| Dyslipidemia (7) | ||||||||
| Prevalence (4) | ||||||||
| Metabolic syndrome (8) | ||||||||
| Hypothyroidism (9) | ||||||||
| Polycystic ovarian syndrome (10) | ||||||||
| Sleep apnea (11) | ||||||||
| Discusses natural course of NAFLD | ||||||||
| Total mortality (12) | ||||||||
| Liver related disease progression (13) | ||||||||
| Cardiovascular disease as most common cause of mortality (14) | ||||||||
| Discusses comorbidity of NAFLD | ||||||||
| Cardiovascular disease (15) | ||||||||
| Diabetes mellitus type II (16) | ||||||||
| Diagnosis of NAFLD | ||||||||
| Discusses about when and which test should be performed to diagnosis and screen of NAFLD. | ||||||||
| Discusses about diagnostic method | ||||||||
| History taking and serologic test for rule out other cause (17) | ||||||||
| Blood liver function test (18) | ||||||||
| Abdominal sonography (19) | ||||||||
| Discusses screening indication | ||||||||
| Insulin resistance patient (20) | ||||||||
| Blood test and abdominal sonography (21) | ||||||||
| Discusses comorbidity screening in NAFLD patient | ||||||||
| Metabolic syndrome (22) | ||||||||
| Cardiovascular disease (23) | ||||||||
| Diabetes mellitus type II (24) | ||||||||
| Discusses non-invasive test about NASH and advanced fibrosis | ||||||||
| Radiology method | ||||||||
| Liver ultrasonography (25) | ||||||||
| Computed tomography (26) | ||||||||
| Magnetic resonance image (27) | ||||||||
| Magnetic resonance spectroscopy (28) | ||||||||
| Elastography | ||||||||
| Transient elastography (29) | ||||||||
| Controlled attenuation parameter (30) | ||||||||
| Magnetic resonance elastography (31) | ||||||||
| Biochemical panel | ||||||||
| NAFLD fibrosis score (32) | ||||||||
| Enhanced liver fibrosis panel (33) | ||||||||
| Cytokeratin-18 fragments (34) | ||||||||
| Discusses liver biopsy indication and efficacy with complication | ||||||||
| Indication (35) | ||||||||
| Efficacy (36) | ||||||||
| Complication (37) | ||||||||
| Management of NAFLD | ||||||||
| Discusses treatment modality of NAFLD | ||||||||
| Lifestyle modification: discusses efficacy and method | ||||||||
| Weight reduction (38) | ||||||||
| Diet (39) | ||||||||
| Exercise (40) | ||||||||
| Drug for weight reduction (41) | ||||||||
| Medical treatment: discusses efficacy and complication | ||||||||
| Anti-oxidant | ||||||||
| Vitamin E (42) | ||||||||
| Other anti-oxidant (43) | ||||||||
| Insulin sensitizer | ||||||||
| Thiazolidinediones (44) | ||||||||
| Metformin (45) | ||||||||
| Lipid lower agents | ||||||||
| Statins (46) | ||||||||
| Fibrates (47) | ||||||||
| Omega-3 polyunsaturated fatty acid supplementation (n-3 PUFAs) (48) | ||||||||
| Ezetimibe (49) | ||||||||
| Pentoxifylline (50) | ||||||||
| Ursodeoxycholic acid (UDCA) (51) | ||||||||
| Angiotensin-II receptor blockers (52) | ||||||||
| Investigating others drugs (53) | ||||||||
| Surgical treatment: discusses indication, efficacy, and complication | ||||||||
| Bariatric surgery | ||||||||
| Indication (54) | ||||||||
| Efficacy (55) | ||||||||
| Complication (56) | ||||||||
NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.
Global quality score criteria used to score the websites with information on non-alcoholic fatty liver disease
| Global score | Description |
|---|---|
| 1 | Poor quality, poor flow of the site, most information missing, not at all useful for patients |
| 2 | Generally poor quality and poor flow, some information listed but many important topics missing, of very limited use to patients |
| 3 | Moderate quality, suboptimal flow, some important information is adequately discussed but others poorly discussed, somewhat useful for patients |
| 4 | Good quality and generally good flow, most of the relevant information is listed, but some topics not covered, useful for patients |
| 5 | Excellent quality and excellent flow, very useful for patients |
Figure 1.Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart showing the websites on non-alcoholic fatty liver disease (NAFLD) searched on the internet and those finally included in the study.
Figure 2.Mean scores for the questions using the DISCERN scale, across the websites evaluated.
Figure 3.Relationship between the global quality score (GQS) and the quality evaluation instrument (QEI) score for evaluating non-alcoholic fatty liver disease websites. The QEI was highly associated with GQS (r = 0.74, p < 0.01).
Grouping the websites on non-alcoholic fatty liver disease included in the study
| Catergory | No. of websites (%) | QEI | Total DISCERN score | GQS | |||
|---|---|---|---|---|---|---|---|
| Mean±SD[ | 95% CI for means | Mean±SD[ | 95% CI for means | Mean±SD[ | 95%CI for means | ||
| Institutional[ | 15 (32) | 11.60 ± 4.80 | 8.93–14.26 | 26.20 ± 5.26 | 23.28–29.11 | 2.13 ± 0.35 | 1.93 to 2.32 |
| Nonpharmaceutical commercial[ | 21 (45) | 9.81 ± 4.98 | 7.54–12.07 | 25.95 ± 6.35 | 23.06–28.84 | 2.09 ± 0.62 | 1.81 to 2.38 |
| Charitable[ | 3 (6) | 5.33 ± 1.15 | 2.46–8.20 | 20.00 ± 2.00 | 15.03–24.96 | 1.33 ± 0.57 | –0.10 to 2.76 |
| Support[ | 8 (17) | 11.12 ± 6.12 | 6.00–16.2 | 23.37 ± 5.92 | 18.42–28.33 | 2.12 ± 0.83 | 1.42 to 2.82 |
| Total | 47 (100) | 10.31 ± 5.09 | 9.02–11.89 | 25.21 ± 5.86 | 23.49–26.93 | 2.06 ± 0.60 | 1.89 to 2.23 |
QEI, quality evaluation instrument; GQS, global quality score; SD, standard deviation; CI, confidence interval.
The QEI scores were not significantly different between the groups as per Kruskal-Wallis test (p = 0.058).
The total DISCERN scores were not significantly different between the groups as per Kruskal-Wallis test (combined, p = 0.211).
The GQS scores were not significantly different between the groups as per Kruskal-Wallis test (combined, p = 0.60).
This category includes government, hospital, or university.
This category includes sponsored sites or private medical sites.
This category include a nonprofit organization.
This category includes personal web pages or patient support groups.